To include your compound in the COVID-19 Resource Center, submit it here.

RG-101: Additional Phase II data

Interim data from 41 evaluable treatment-naive patients with chronic HCV genotype 1 or 4 infection in a Phase II trial showed

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE